MedTrace Logo

Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome

NCT00732680 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2016-04-18

Study results available
· View outcomes & findings →

Summary

Empty Nose Syndrome patients suffer from disabling physical symptoms and considerable distress. To date there is no definitive cure for these symptoms. Established treatment modalities include saline irrigation, surgical implantation of materials or simply use of cotton wads/ silicon cones to simulate the resistive action to airflow of the resected turbinates.

This study will research the effectiveness of a new treatment modality in the treatment of Empty Nose Syndrome. This novel treatment method involves the use of botulinum toxin type A (Botox).

Conditions

  • Empty Nose Syndrome
  • Atrophic Rhinitis

Interventions

DRUG

Botulinum Toxin Type A

10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.

Sponsors & Collaborators

Principal Investigators

  • Oren Friedman, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732680 on ClinicalTrials.gov